You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK)「百拓維」治療前列腺癌獲批上市 將與百濟神州(06160.HK)開展商業化合作
綠葉製藥(02186.HK)公布,集團自主研發的創新制劑注射用戈舍瑞林微球(LY01005),又名「百拓維」,已於6月30日獲得中國國家藥監局批准上市,用於治療需要雄激素去勢治療的前列腺癌患者。 公司表示,該產品為全球首個且當前唯一獲批上市的戈舍瑞林長效微球制劑,將與百濟神州(06160.HK)共同開展該產品商業化合作。 綠葉製藥又指,除了前列腺癌外,百拓維用於治療乳腺癌的新藥上市許可申請目前亦在中國處於審評階段。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account